MedDataX Logo

Clinical Decision Support Tools to Increase Human Papillomavirus (HPV) Vaccination in Adolescents in Pharmacies

NCT ID: NCT05831540

Last Updated: 2024-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-28

Study Completion Date

2024-11-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial develops and tests how well a clinical decision support (CDS) tool works to increase human papillomavirus (HPV) vaccination of children between the age of 9-17 (adolescents) in pharmacies. HPV vaccination rate in eligible adolescents remains low even though over 90% of the cancers in adults caused by HPV can be prevented by the HPV vaccine. The National Vaccine Advisory Committee recommends HPV vaccinations to be given in pharmacies to increase access to vaccines, but pharmacy processes and lack of awareness of the service among parents impact the use of local pharmacies for HPV vaccinations. Using a focus group may be an effective method to develop a CDS tool and create a process that may be more convenient for parents to get their adolescent's vaccine at their local pharmacy. A CDS tool may make it easier to obtain HPV vaccines, and as a result increase the adolescent HPV vaccination rate and reduce the incidence of cancer caused by HPV.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OUTLINE: Participants are assigned to 1 of 3 groups.

Group I: Staff participate in facilitated planning discussions to develop CDS tools on study. (Aim I)

Group II: Staff receives CDS tools training and implements CDS tools to facilitate HPV vaccination on study. (Aim II)

Group III: Parents complete survey post-intervention on study. (Aim II)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Papillomavirus-Related Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group I (staff focus group)

Staff participate in facilitated planning discussions to develop CDS tools on study.

Group Type EXPERIMENTAL

Discussion

Intervention Type OTHER

Participate in focus group

Survey Administration

Intervention Type OTHER

Complete survey

Group II (staff CDS tool utilization)

Staff receives CDS tools training and implements CDS tools to facilitate HPV vaccination on study.

Group Type EXPERIMENTAL

Educational Activity

Intervention Type OTHER

Undergo training to use CDS tool

Healthcare Activity

Intervention Type BEHAVIORAL

Utilize CDS tool

Survey Administration

Intervention Type OTHER

Complete survey

Group III (parent survey)

Parents complete survey post-intervention on study.

Group Type EXPERIMENTAL

Survey Administration

Intervention Type OTHER

Complete survey

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Discussion

Participate in focus group

Intervention Type OTHER

Educational Activity

Undergo training to use CDS tool

Intervention Type OTHER

Healthcare Activity

Utilize CDS tool

Intervention Type BEHAVIORAL

Survey Administration

Complete survey

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Discuss Health Care Activity Healthcare

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* AIM I: \>= 18 years
* AIM I: Pharmacy staff: Employed at the partnering community pharmacies in Washington state
* AIM I: Scientific Technologies Corportation (STC)Health staff: Employed at STCHealth
* AIM I: PioneerRx staff: Employed at PioneerRx
* AIM II: \>= 18 years
* AIM II: Parents: English speaking parent or guardian of at least one child, ages 9-17, living in Washington state and obtained an HPV vaccination for their child at a participating pharmacy and have access to a telephone or computer with internet access.
* AIM II: Pharmacy staff: Employed at community pharmacies recruited into the study located in Washington state

Exclusion Criteria

* Pharmacy staff: Floaters/per diem. Those who object to having the focus group discussions audio recorded. Those who object to participating in implementation evaluation surveys
* STCHealth staff: Those who object to having the focus group discussions audio recorded
* PioneerRx staff: Those who object to having the focus group discussions audio recorded
* Parents: Those who decline to provide feedback on their experiences with getting their children vaccinated at the pharmacy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fred Hutchinson Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Parth Shah

Role: PRINCIPAL_INVESTIGATOR

Fred Hutch/University of Washington Cancer Consortium

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2023-01989

Identifier Type: REGISTRY

Identifier Source: secondary_id

11086

Identifier Type: OTHER

Identifier Source: secondary_id

RG1122655

Identifier Type: -

Identifier Source: org_study_id